* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
PROTAC has been successfully applied in target protein degradation, which is achieved by utilizing intracellular ubiquitin proteasomal system (UPS). The UPS is pivotal in the regulation of almost all cellular processes, including immune response, inflammation, apoptosis, and so forth. PROTACs are promising in autoimmune diseases treatment and some of them have been successfully developed to enter early clinical studies. As an expert in PROTAC development, BOC Sciences offers comprehensive PROTAC design and development services for autoimmune diseases drug discovery. We offer one-stop services to help our customers accelerate the development of new drugs.
Immune system is to protect the body from bacteria, parasites, viruses and cancer cells. However, the overactive immune system may cause autoimmune diseases. Autoimmune diseases refer to the body’s immune response to self-antigens causes damage to its own tissues, which are caused by acquired immune dysfunction and characterized by different degrees of damage to cells and tissues, even organ failure and death. The common autoimmune diseases include multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis, psoriasis, Type 1 diabetes mellitus, etc.
A PROTAC is a bifunctional molecule that consists of three parts: a ligand that interacts with the protein to be degraded (warhead ligand), a different ligand that binds to an E3 ubiquitin ligase and a linker that connects both ligands. PROTACs have shown strong potency in disease treatment, some of them have reached the clinical phase, like those developed against the IRAK4 in autoimmune diseases.
The vast majority of newly developed PROTACs currently in clinical trials target a variety of cancers. However, given their potential to degrade undruggable targets, the scope of PROTAC is expanding beyond oncology. With the development of PROTAC technology, this innovative therapeutic approach shows its potential in autoimmune diseases treatment. Two PROTAC compounds already in phase I clinical trials that could test PROTAC modality in non-oncology indications are KT-474, and NX-5948, targeting BTK and IRAK4, respectively, both in Phase I clinical trials for the treatment of various immunoinflammatory diseases, such as rheumatoid arthritis.
In academia, there are many PROTACs have been developed for autoimmune diseases. For example, a series of PROTAC molecules targeting IRAK4 have been reported. Molecular docking studies based on the crystal structures of IRAK4 and its kinase inhibitor complexes successfully predicted the optimal location for binding IRAK4 ligands. Finally, multiple IRAK4 PROTAC molecules were generated by assembling E3 ligands, linker and IRAK4 ligands.
Fig 1. Co-crystal structure of inhibitor with IRAK4 kinase domain (Nunes, 2019)
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
Please contact us with any specific requirements and we will get back to you as soon as possible.